EA005002B1 - НОВЫЕ ТЕРАПЕВТИЧЕСКИЕ КОМБИНАЦИИ (S)-2-(БЕНЗИЛАМИНОМЕТИЛ)-2,3,8,9-ТЕТРАГИДРО-7H-1,4-ДИОКСИН [2,3-e]ИНДОЛ-8-ОНА И НЕЙРОЛЕПТИКОВ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ПСИХОТИЧЕСКИХ РАССТРОЙСТВ - Google Patents

НОВЫЕ ТЕРАПЕВТИЧЕСКИЕ КОМБИНАЦИИ (S)-2-(БЕНЗИЛАМИНОМЕТИЛ)-2,3,8,9-ТЕТРАГИДРО-7H-1,4-ДИОКСИН [2,3-e]ИНДОЛ-8-ОНА И НЕЙРОЛЕПТИКОВ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ПСИХОТИЧЕСКИХ РАССТРОЙСТВ Download PDF

Info

Publication number
EA005002B1
EA005002B1 EA200200656A EA200200656A EA005002B1 EA 005002 B1 EA005002 B1 EA 005002B1 EA 200200656 A EA200200656 A EA 200200656A EA 200200656 A EA200200656 A EA 200200656A EA 005002 B1 EA005002 B1 EA 005002B1
Authority
EA
Eurasian Patent Office
Prior art keywords
antipsychotic agent
antipsychotic
tetrahydro
indol
patient
Prior art date
Application number
EA200200656A
Other languages
English (en)
Russian (ru)
Other versions
EA200200656A1 (ru
Inventor
Карен Лавелл Марквис
Original Assignee
Уайт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Уайт filed Critical Уайт
Publication of EA200200656A1 publication Critical patent/EA200200656A1/ru
Publication of EA005002B1 publication Critical patent/EA005002B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA200200656A 1999-12-10 2000-12-07 НОВЫЕ ТЕРАПЕВТИЧЕСКИЕ КОМБИНАЦИИ (S)-2-(БЕНЗИЛАМИНОМЕТИЛ)-2,3,8,9-ТЕТРАГИДРО-7H-1,4-ДИОКСИН [2,3-e]ИНДОЛ-8-ОНА И НЕЙРОЛЕПТИКОВ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ПСИХОТИЧЕСКИХ РАССТРОЙСТВ EA005002B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45860799A 1999-12-10 1999-12-10
PCT/US2000/033060 WO2001041750A2 (fr) 1999-12-10 2000-12-07 Nouvelles combinaisons therapeutiques de (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one et neuroleptiques destines au traitement ou a la prevention de troubles psychotiques

Publications (2)

Publication Number Publication Date
EA200200656A1 EA200200656A1 (ru) 2002-12-26
EA005002B1 true EA005002B1 (ru) 2004-10-28

Family

ID=23821437

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200656A EA005002B1 (ru) 1999-12-10 2000-12-07 НОВЫЕ ТЕРАПЕВТИЧЕСКИЕ КОМБИНАЦИИ (S)-2-(БЕНЗИЛАМИНОМЕТИЛ)-2,3,8,9-ТЕТРАГИДРО-7H-1,4-ДИОКСИН [2,3-e]ИНДОЛ-8-ОНА И НЕЙРОЛЕПТИКОВ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ПСИХОТИЧЕСКИХ РАССТРОЙСТВ

Country Status (20)

Country Link
EP (1) EP1235570A2 (fr)
JP (1) JP5557409B2 (fr)
KR (1) KR100772854B1 (fr)
CN (1) CN1230164C (fr)
AR (1) AR026756A1 (fr)
AU (1) AU784211B2 (fr)
BR (1) BR0016168A (fr)
CA (1) CA2396351C (fr)
CZ (1) CZ20021880A3 (fr)
EA (1) EA005002B1 (fr)
HK (1) HK1045942A1 (fr)
HU (1) HUP0203309A3 (fr)
IL (2) IL149669A0 (fr)
MX (1) MXPA02005649A (fr)
NO (1) NO20022739D0 (fr)
NZ (1) NZ519381A (fr)
PL (1) PL355292A1 (fr)
TW (1) TWI222864B (fr)
WO (1) WO2001041750A2 (fr)
ZA (1) ZA200205484B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2481123C2 (ru) * 2008-02-13 2013-05-10 Таргасепт, Инк. Комбинация агонистов альфа 7 никотиновых рецепторов и антипсихотических средств

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG147450A1 (en) 2003-10-29 2008-11-28 Wyeth Corp Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
CA2597616A1 (fr) 2005-02-17 2006-08-24 Wyeth Derive d'indole, benzothiophene, benzofurane et indene a fusion cycloalkyle

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2987484B2 (ja) * 1995-03-16 1999-12-06 大塚製薬 株式会社 カルボスチリル誘導体の製造方法
US5756532A (en) 1995-11-06 1998-05-26 American Home Products Corporation Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives
GB9627005D0 (en) * 1996-12-27 1997-02-12 Knoll Ag Therapeutic agents

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2481123C2 (ru) * 2008-02-13 2013-05-10 Таргасепт, Инк. Комбинация агонистов альфа 7 никотиновых рецепторов и антипсихотических средств

Also Published As

Publication number Publication date
TWI222864B (en) 2004-11-01
BR0016168A (pt) 2002-08-20
AR026756A1 (es) 2003-02-26
HUP0203309A2 (hu) 2003-01-28
CA2396351C (fr) 2009-11-10
CA2396351A1 (fr) 2001-06-14
NZ519381A (en) 2004-04-30
CZ20021880A3 (cs) 2002-08-14
AU1949001A (en) 2001-06-18
WO2001041750A3 (fr) 2002-02-14
EA200200656A1 (ru) 2002-12-26
CN1230164C (zh) 2005-12-07
CN1409633A (zh) 2003-04-09
JP5557409B2 (ja) 2014-07-23
KR20030016207A (ko) 2003-02-26
AU784211B2 (en) 2006-02-23
PL355292A1 (en) 2004-04-05
ZA200205484B (en) 2003-12-31
NO20022739L (no) 2002-06-07
HK1045942A1 (zh) 2002-12-20
KR100772854B1 (ko) 2007-11-02
MXPA02005649A (es) 2004-09-10
WO2001041750A2 (fr) 2001-06-14
JP2003516350A (ja) 2003-05-13
HUP0203309A3 (en) 2004-12-28
NO20022739D0 (no) 2002-06-07
IL149669A0 (en) 2002-11-10
EP1235570A2 (fr) 2002-09-04
IL149669A (en) 2006-06-11

Similar Documents

Publication Publication Date Title
EP1994932A1 (fr) Utilisation de N-desmethylclozapine pour traiter les psychoses humaines
US20150352107A1 (en) Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions
EP2608670B1 (fr) Procédés de traitement de la prise de poids induite par des neuroleptiques
US20090258084A1 (en) Mono and Combination Therapy with a M1/M4 Muscarinic Agonist (Sabcomeline) for Treatment of Cognitive Disorders in Schizophrenia
US20090306040A1 (en) Mono and Combination Therapy of M1/M4 Agonist (Sabcomeline) for Treatment of Negative Symptoms of Schizophrenia
US20070238725A1 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
US20090318414A1 (en) Mono and Combination Therapy with M1/M4 Muscarinic Agonist (Sabcomeline) for Treatment of Prodromal Syndrome
US6350773B1 (en) Therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro 7H-1,4-dioxino{2,3-e}indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders
EA005002B1 (ru) НОВЫЕ ТЕРАПЕВТИЧЕСКИЕ КОМБИНАЦИИ (S)-2-(БЕНЗИЛАМИНОМЕТИЛ)-2,3,8,9-ТЕТРАГИДРО-7H-1,4-ДИОКСИН [2,3-e]ИНДОЛ-8-ОНА И НЕЙРОЛЕПТИКОВ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ПСИХОТИЧЕСКИХ РАССТРОЙСТВ
AU2004246820B2 (en) Asenapine for the treatment of schizophrenia in a patient with overweight or predisposition for overweight
Cheng et al. Dopamine hypothesis

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU